Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.88 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 6/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104875 | 1.00 | METTL3 (0.88) | METTL3GAAEGFRMAPTCFD | |
| SCHEMBL13693054 | 0.94 | METTL3 (0.86) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL13942147 | 0.94 | METTL3 (0.86) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL13596336 | 0.93 | METTL3 (0.77) | METTL3GAAEGFRMAPTCFD | |
| Elvitegravir SCHEMBL29623981 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL726251 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL726252 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL13225651 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL11948686 | 0.93 | METTL3 (0.76) | METTL3GAAEGFRMAPTCFD | |
| Elvitegravir SCHEMBL1050769 | 0.93 | METTL3 (0.98) | METTL3GAAEGFRMAPTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028535-A1 | 3-HYDROXYPYRIMIDINE-2,4-DIONE-5-CARBOXAMIDES AS POTENT INHIBITORS OF HIV | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028535-A1 | 3-HYDROXYPYRIMIDINE-2,4-DIONE-5-CARBOXAMIDES AS POTENT INHIBITORS OF HIV | DPYD, IMPDH2, TYMP | METTL3 2004/4885GAA 3701/4885EGFR 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.